SignalCorporate

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Revenue miss outweighs LYMPHIR launch momentum, triggering sharp share decline.

What changed

Revenue miss outweighs LYMPHIR launch momentum, triggering sharp share decline.

Why it matters

Revenue miss outweighs LYMPHIR launch momentum, triggering sharp share decline. — impact context not separately stored; see What changed.

Sources